1. The FDA asked Endo to remove its opioid painkiller Opana ER from the market, citing public health reasons related to opioid abuse and misuse. (Reuters)

2. Eli Lilly paid $55 million to partner with Swiss biotech company KeyBioscience to develop a class of drugs intended to address insulin sensitivity and weight loss for patients with diabetes. (Endpoints News)

3. The House Energy & Commerce Committee unanimously voted in favor of advancing PDUFA legislation to the House floor. The bill no longer includes a provision expanding off-label marketing. (Inside Health Policy)

4. Several drugmakers, including Dr. Reddy’s Laboratories, Mylan, Novartis, and Sun Pharmaceutical Industries, allegedly agreed to raise their generic drug prices to prevent competition, according to four antitrust lawsuits filed in Pennsylvania. (Law 360)

5. Valeant plans to sell its prescription and over-the-counter business iNova Pharmaceuticals for $930 million by the second half of 2017. The business markets weight and pain management, cardiology, and cold-and-cough drugs. (WSJ)